サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1551462

化学療法誘発性好中球減少症の治療の世界市場

Chemotherapy-Induced Neutropenia Treatment
出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 381 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=150.96円
化学療法誘発性好中球減少症の治療の世界市場
出版日: 2024年09月10日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 381 Pages
納期: 即日から翌営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

化学療法誘発性好中球減少症の治療の世界市場は2030年までに6億5,990万米ドルに達する見込み

2023年に5億6,690万米ドルと推定される化学療法誘発性好中球減少症の治療の世界市場は、2030年には6億5,990万米ドルに達し、分析期間2023-2030年のCAGRは2.2%で成長すると予測されます。顆粒球コロニー刺激因子療法（Granulocyte Colony-Stimulating Factors Therapy）は、本レポートで分析したセグメントの1つであり、CAGR 3.3%を記録し、分析期間終了までに2億5,920万米ドルに達すると予測されます。抗生物質療法分野の成長率は、分析期間中CAGR 1.7%と推定されます。

米国市場は1億5,450万米ドルと推定、中国はCAGR4.7%で成長予測

米国の化学療法誘発性好中球減少症の治療市場は、2023年に1億5,450万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに1億3,120万米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは4.7%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ0.5％と1.6％と予測されています。欧州では、ドイツがCAGR 1.0%で成長すると予測されています。

世界の化学療法誘発性好中球減少症の治療市場- 主要動向と促進要因まとめ

化学療法誘発性好中球減少症とは何か？

化学療法誘発性好中球減少症は、がん治療の重篤な副作用であり、感染症と闘うために重要な白血球の一種である好中球の数を減少させることによって免疫系を著しく損なう。好中球減少症は、化学療法が急速に分裂する細胞を標的とするために起こりますが、これはがん細胞と好中球を産生する骨髄などの健康な細胞の両方の特徴です。その結果、好中球の数が減少するため、患者さんは感染症に非常にかかりやすくなり、速やかに対処しなければ生命を脅かすことになります。感染症のリスクは好中球減少症の重症度が高いほど高くなり、軽度の感染症であっても重篤な合併症や入院、がん治療の遅れにつながる可能性があります。したがって、化学療法による好中球減少症を管理することは、がん患者の健康と安全を維持するために不可欠であり、これにより、がん患者は治療の中断を少なくし、合併症のリスクを低減しながら治療レジメンを継続することができます。

化学療法誘発性好中球減少症の治療における現在の戦略と課題とは？

化学療法による好中球減少症に対する治療戦略は、主に感染症の予防と患者の免疫系のサポートに焦点を当てています。最も一般的なアプローチは、フィルグラスチム、ペグフィルグラスチム、バイオシミラーなどの顆粒球コロニー刺激因子（G-CSF）の使用であり、これらは骨髄における好中球の産生を刺激します。これらの薬剤は通常、好中球減少の期間と重症度を軽減するために化学療法後に注射として投与されます。抗生物質の予防投与は、重症好中球減少症の患者の感染症を予防するために用いられるもう一つの戦略です。しかし、これらの治療に課題がないわけではないです。G-CSF療法は高価であり、骨痛やまれに脾臓破裂などの副作用を伴う。さらに、合併症を避けるためには、G-CSF投与のタイミングと投与量を注意深く管理しなければならないです。さらに、すべての患者がこれらの治療に反応するわけではなく、入院や集中治療を必要とする好中球減少症のエピソードを経験する患者もいます。抗生物質に対する耐性の発達も重要な課題であり、新しい治療アプローチとより個別化された治療戦略の必要性を強調しています。

ヘルスケアプロバイダーは臨床現場で化学療法誘発性好中球減少症をどのように管理しているか？

臨床現場における化学療法誘発性好中球減少症の効果的な管理には、積極的なモニタリング、時宜を得た介入、および患者教育を組み合わせることが必要です。腫瘍医は通常、化学療法を開始する前に、年齢、全身の健康状態、特定の化学療法の種類と用量などの因子を考慮して、患者の好中球減少症のリスクを評価します。リスクが高い患者にはG-CSFの予防的投与が推奨されます。治療中は、定期的な血液検査で好中球数を追跡し、好中球減少の早期徴候を検出することで、患者さんを注意深く観察します。好中球減少が発現した場合は、好中球数が回復するまで化学療法の投与量を減らしたり、その後のサイクルを遅らせたりして治療計画を調整します。良好な衛生習慣、感染因子への曝露の回避、感染の初期徴候の認識に関する患者教育などの感染予防対策は、ケアの重要な要素です。さらに、発熱性好中球減少症（発熱と好中球数の減少を特徴とする緊急医療）の場合は、状態を管理し、さらなる合併症を予防するために、早急な入院と積極的な抗生物質療法が必要となります。

化学療法誘発性好中球減少症の治療市場の成長を促進する要因は？

化学療法誘発性好中球減少症の治療市場の成長は、世界のがん罹患率の増加、効果的ながん治療や支持療法に対する需要の高まりなど、いくつかの要因によって牽引されています。化学療法や標的がん治療の進歩は、生存率を向上させる一方で、好中球減少症の発生率の増加にも寄与しており、より強固な管理ソリューションが必要とされています。バイオシミラーのイントロダクションはG-CSF療法をより身近で手頃なものにし、それによって市場は拡大しています。さらに、個別化医療への注目の高まりが、個々の患者のリスクプロファイルに基づいて好中球減少症の管理を最適化するオーダーメイド治療レジメンの開発を促進しています。また、新興市場におけるヘルスケアのインフラ整備と高度ながん治療へのアクセスの向上も、G-CSFのような支持療法を含む包括的ながん治療を受けられる患者が増加するにつれて、市場の成長に寄与しています。さらに、好中球減少症治療の有効性と安全性の向上を目指した研究開発が進められており、この重要な化学療法の副作用をよりよく管理するための新たな希望がもたらされることで、市場はさらに成長すると予想されます。

調査対象企業の例（注目の48社）

  • AbbVie, Inc.
  • Amgen Inc.
  • Aurobindo Pharma Ltd.
  • BeyondSpring Pharmaceuticals Inc.
  • Biocon Ltd.
  • Coherus Biosciences, Inc.
  • Evive Biotech
  • G1 Therapeutics, Inc.
  • GSK Plc
  • Kyowa Kirin Co., Ltd.
  • Merck & Co., Inc.
  • Myelo Therapeutics GmbH
  • Novartis Pharmaceuticals Corporation
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.;

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP24650

Global Chemotherapy-Induced Neutropenia Treatment Market to Reach US$659.9 Million by 2030

The global market for Chemotherapy-Induced Neutropenia Treatment estimated at US$566.9 Million in the year 2023, is expected to reach US$659.9 Million by 2030, growing at a CAGR of 2.2% over the analysis period 2023-2030. Granulocyte Colony-Stimulating Factors Therapy, one of the segments analyzed in the report, is expected to record a 3.3% CAGR and reach US$259.2 Million by the end of the analysis period. Growth in the Antibiotic Therapy segment is estimated at 1.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$154.5 Million While China is Forecast to Grow at 4.7% CAGR

The Chemotherapy-Induced Neutropenia Treatment market in the U.S. is estimated at US$154.5 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$131.2 Million by the year 2030 trailing a CAGR of 4.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.5% and 1.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.0% CAGR.

Global Chemotherapy-Induced Neutropenia Treatment Market - Key Trends and Drivers Summarized

What Is Chemotherapy-Induced Neutropenia, and Why Is It a Major Concern?

Chemotherapy-induced neutropenia is a severe side effect of cancer treatment that significantly compromises the immune system by reducing the number of neutrophils, a type of white blood cell crucial for fighting infections. Neutropenia occurs because chemotherapy targets rapidly dividing cells, a characteristic of both cancerous cells and healthy cells such as those in the bone marrow that produce neutrophils. The resulting decrease in neutrophil count leaves patients highly vulnerable to infections, which can become life-threatening if not promptly addressed. The risk of infection increases with the severity of neutropenia, and even minor infections can lead to serious complications, hospitalizations, and delays in cancer treatment. Therefore, managing chemotherapy-induced neutropenia is essential for maintaining the health and safety of cancer patients, enabling them to continue their treatment regimens with fewer interruptions and a reduced risk of complications.

What Are the Current Strategies and Challenges in Chemotherapy-Induced Neutropenia Treatment?

Treatment strategies for chemotherapy-induced neutropenia focus primarily on preventing infections and supporting the patient's immune system. The most common approach involves the use of granulocyte colony-stimulating factors (G-CSFs) such as filgrastim, pegfilgrastim, and biosimilars, which stimulate the production of neutrophils in the bone marrow. These agents are typically administered as injections following chemotherapy to reduce the duration and severity of neutropenia. Antibiotic prophylaxis is another strategy used to prevent infections in patients with severe neutropenia. However, these treatments are not without challenges. G-CSF therapy can be expensive and is associated with side effects like bone pain and, in rare cases, splenic rupture. Moreover, the timing and dosage of G-CSF administration must be carefully managed to avoid complications. Additionally, not all patients respond to these treatments, and some may still experience episodes of neutropenia, requiring hospitalization and intensive care. The development of resistance to antibiotics also poses a significant challenge, underscoring the need for new therapeutic approaches and more personalized treatment strategies.

How Do Healthcare Providers Manage Chemotherapy-Induced Neutropenia in Clinical Settings?

Effective management of chemotherapy-induced neutropenia in clinical settings involves a combination of proactive monitoring, timely intervention, and patient education. Oncologists typically assess a patient’s risk of neutropenia before starting chemotherapy, considering factors such as age, overall health, and the specific type and dose of chemotherapy. For patients at high risk, prophylactic administration of G-CSFs is recommended. During treatment, patients are closely monitored through regular blood tests to track neutrophil counts and detect early signs of neutropenia. If neutropenia develops, the treatment plan may be adjusted by lowering the dose of chemotherapy or delaying subsequent cycles until the neutrophil count recovers. Infection prevention measures, including good hygiene practices, avoiding exposure to infectious agents, and patient education on recognizing early signs of infection, are critical components of care. Additionally, in cases of febrile neutropenia—a medical emergency characterized by fever and low neutrophil count—immediate hospitalization and aggressive antibiotic therapy are required to manage the condition and prevent further complications.

What Factors Are Driving the Growth of the Chemotherapy-Induced Neutropenia Treatment Market?

The growth in the chemotherapy-induced neutropenia treatment market is driven by several factors, including the increasing prevalence of cancer worldwide, which is leading to a higher demand for effective cancer treatments and supportive care therapies. Advances in chemotherapy and targeted cancer therapies, while improving survival rates, have also contributed to the increased incidence of neutropenia, necessitating more robust management solutions. The introduction of biosimilars has made G-CSF therapy more accessible and affordable, thereby expanding the market. Additionally, the growing focus on personalized medicine is driving the development of tailored treatment regimens that optimize the management of neutropenia based on individual patient risk profiles. The rise in healthcare infrastructure and access to advanced cancer care in emerging markets is also contributing to market growth, as more patients gain access to comprehensive cancer treatment, including supportive therapies like G-CSFs. Moreover, ongoing research and development efforts aimed at improving the efficacy and safety of neutropenia treatments are expected to further propel the market, offering new hope for better management of this critical chemotherapy side effect.

Select Competitors (Total 48 Featured) -

  • AbbVie, Inc.
  • Amgen Inc.
  • Aurobindo Pharma Ltd.
  • BeyondSpring Pharmaceuticals Inc.
  • Biocon Ltd.
  • Coherus Biosciences, Inc.
  • Evive Biotech
  • G1 Therapeutics, Inc.
  • GSK Plc
  • Kyowa Kirin Co., Ltd.
  • Merck & Co., Inc.
  • Myelo Therapeutics GmbH
  • Novartis Pharmaceuticals Corporation
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Chemotherapy-Induced Neutropenia Treatment - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Incidence of Cancer Propels Growth in Chemotherapy-Induced Neutropenia Treatment
    • Advancements in Chemotherapy Protocols Drive Demand for Effective Neutropenia Management
    • Development of Novel Growth Factor Therapies Expands Treatment Options and Market Opportunities
    • Rising Adoption of Targeted Therapies Drives the Need for Supportive Care in Neutropenia
    • Improved Patient Survival Rates Sustain Growth in Neutropenia Treatment Demand
    • Shift Toward Personalized Medicine Spurs Innovation in Chemotherapy-Induced Neutropenia Therapies
    • Increasing Awareness and Early Detection of Neutropenia Fuel Market Expansion
    • Introduction of Biosimilars Generates Competitive Pricing and Market Growth
    • Integration of Digital Health Solutions Drives Adoption of Comprehensive Neutropenia Management Strategies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Chemotherapy-Induced Neutropenia Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Chemotherapy-Induced Neutropenia Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Granulocyte Colony-Stimulating Factors Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Granulocyte Colony-Stimulating Factors Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Granulocyte Colony-Stimulating Factors Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Antibiotic Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Antibiotic Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Antibiotic Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Granulocyte Transfusion Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Granulocyte Transfusion Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Granulocyte Transfusion Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Therapy Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Therapy Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Other Therapy Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Branded Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Branded Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Branded Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Biosimilars Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Biosimilars Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Biosimilars Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Chemotherapy-Induced Neutropenia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Percentage Breakdown of Value Sales for Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Branded Drug Class and Biosimilars Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Branded Drug Class and Biosimilars Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Percentage Breakdown of Value Sales for Branded Drug Class and Biosimilars Drug Class for the Years 2014, 2024 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Percentage Breakdown of Value Sales for Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Branded Drug Class and Biosimilars Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Branded Drug Class and Biosimilars Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Percentage Breakdown of Value Sales for Branded Drug Class and Biosimilars Drug Class for the Years 2014, 2024 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • JAPAN
    • Chemotherapy-Induced Neutropenia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Percentage Breakdown of Value Sales for Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Branded Drug Class and Biosimilars Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Branded Drug Class and Biosimilars Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Percentage Breakdown of Value Sales for Branded Drug Class and Biosimilars Drug Class for the Years 2014, 2024 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • CHINA
    • Chemotherapy-Induced Neutropenia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: China 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Percentage Breakdown of Value Sales for Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Branded Drug Class and Biosimilars Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Branded Drug Class and Biosimilars Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: China 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Percentage Breakdown of Value Sales for Branded Drug Class and Biosimilars Drug Class for the Years 2014, 2024 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: China 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • EUROPE
    • Chemotherapy-Induced Neutropenia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Chemotherapy-Induced Neutropenia Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Percentage Breakdown of Value Sales for Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Branded Drug Class and Biosimilars Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Branded Drug Class and Biosimilars Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Percentage Breakdown of Value Sales for Branded Drug Class and Biosimilars Drug Class for the Years 2014, 2024 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • FRANCE
    • Chemotherapy-Induced Neutropenia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: France 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Percentage Breakdown of Value Sales for Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Branded Drug Class and Biosimilars Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Branded Drug Class and Biosimilars Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: France 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Percentage Breakdown of Value Sales for Branded Drug Class and Biosimilars Drug Class for the Years 2014, 2024 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: France 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • GERMANY
    • Chemotherapy-Induced Neutropenia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Germany 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Percentage Breakdown of Value Sales for Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Branded Drug Class and Biosimilars Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Branded Drug Class and Biosimilars Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Percentage Breakdown of Value Sales for Branded Drug Class and Biosimilars Drug Class for the Years 2014, 2024 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Italy 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Percentage Breakdown of Value Sales for Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Branded Drug Class and Biosimilars Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Branded Drug Class and Biosimilars Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Percentage Breakdown of Value Sales for Branded Drug Class and Biosimilars Drug Class for the Years 2014, 2024 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Chemotherapy-Induced Neutropenia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 107: UK Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: UK 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Percentage Breakdown of Value Sales for Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Branded Drug Class and Biosimilars Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Branded Drug Class and Biosimilars Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Percentage Breakdown of Value Sales for Branded Drug Class and Biosimilars Drug Class for the Years 2014, 2024 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 118: Spain 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Percentage Breakdown of Value Sales for Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Branded Drug Class and Biosimilars Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Branded Drug Class and Biosimilars Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 121: Spain 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Percentage Breakdown of Value Sales for Branded Drug Class and Biosimilars Drug Class for the Years 2014, 2024 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 124: Spain 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 127: Russia 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Percentage Breakdown of Value Sales for Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Branded Drug Class and Biosimilars Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Branded Drug Class and Biosimilars Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 130: Russia 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Percentage Breakdown of Value Sales for Branded Drug Class and Biosimilars Drug Class for the Years 2014, 2024 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 133: Russia 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 136: Rest of Europe 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Percentage Breakdown of Value Sales for Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Branded Drug Class and Biosimilars Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Branded Drug Class and Biosimilars Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 139: Rest of Europe 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Percentage Breakdown of Value Sales for Branded Drug Class and Biosimilars Drug Class for the Years 2014, 2024 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 142: Rest of Europe 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Chemotherapy-Induced Neutropenia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Chemotherapy-Induced Neutropenia Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 145: Asia-Pacific 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 148: Asia-Pacific 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Percentage Breakdown of Value Sales for Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Branded Drug Class and Biosimilars Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Branded Drug Class and Biosimilars Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Percentage Breakdown of Value Sales for Branded Drug Class and Biosimilars Drug Class for the Years 2014, 2024 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Chemotherapy-Induced Neutropenia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 157: Australia 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Percentage Breakdown of Value Sales for Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Branded Drug Class and Biosimilars Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Branded Drug Class and Biosimilars Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 160: Australia 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Percentage Breakdown of Value Sales for Branded Drug Class and Biosimilars Drug Class for the Years 2014, 2024 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 163: Australia 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • INDIA
    • Chemotherapy-Induced Neutropenia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 164: India Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 166: India 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Percentage Breakdown of Value Sales for Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Branded Drug Class and Biosimilars Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Branded Drug Class and Biosimilars Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 169: India 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Percentage Breakdown of Value Sales for Branded Drug Class and Biosimilars Drug Class for the Years 2014, 2024 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 172: India 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 175: South Korea 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Percentage Breakdown of Value Sales for Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Branded Drug Class and Biosimilars Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Branded Drug Class and Biosimilars Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 178: South Korea 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Percentage Breakdown of Value Sales for Branded Drug Class and Biosimilars Drug Class for the Years 2014, 2024 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 181: South Korea 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Percentage Breakdown of Value Sales for Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Branded Drug Class and Biosimilars Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Branded Drug Class and Biosimilars Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Percentage Breakdown of Value Sales for Branded Drug Class and Biosimilars Drug Class for the Years 2014, 2024 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Chemotherapy-Induced Neutropenia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Chemotherapy-Induced Neutropenia Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 193: Latin America 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 196: Latin America 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Percentage Breakdown of Value Sales for Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Branded Drug Class and Biosimilars Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Branded Drug Class and Biosimilars Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Percentage Breakdown of Value Sales for Branded Drug Class and Biosimilars Drug Class for the Years 2014, 2024 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 205: Argentina 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Percentage Breakdown of Value Sales for Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Branded Drug Class and Biosimilars Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Branded Drug Class and Biosimilars Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 208: Argentina 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Percentage Breakdown of Value Sales for Branded Drug Class and Biosimilars Drug Class for the Years 2014, 2024 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 211: Argentina 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 214: Brazil 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Percentage Breakdown of Value Sales for Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Branded Drug Class and Biosimilars Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Branded Drug Class and Biosimilars Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 217: Brazil 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Percentage Breakdown of Value Sales for Branded Drug Class and Biosimilars Drug Class for the Years 2014, 2024 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 220: Brazil 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 223: Mexico 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Percentage Breakdown of Value Sales for Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Branded Drug Class and Biosimilars Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Branded Drug Class and Biosimilars Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 226: Mexico 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Percentage Breakdown of Value Sales for Branded Drug Class and Biosimilars Drug Class for the Years 2014, 2024 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 229: Mexico 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 232: Rest of Latin America 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Percentage Breakdown of Value Sales for Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Branded Drug Class and Biosimilars Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Branded Drug Class and Biosimilars Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 235: Rest of Latin America 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Percentage Breakdown of Value Sales for Branded Drug Class and Biosimilars Drug Class for the Years 2014, 2024 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 238: Rest of Latin America 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Chemotherapy-Induced Neutropenia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Chemotherapy-Induced Neutropenia Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 241: Middle East 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 244: Middle East 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Percentage Breakdown of Value Sales for Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Branded Drug Class and Biosimilars Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Branded Drug Class and Biosimilars Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Percentage Breakdown of Value Sales for Branded Drug Class and Biosimilars Drug Class for the Years 2014, 2024 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 253: Iran 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Percentage Breakdown of Value Sales for Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Branded Drug Class and Biosimilars Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Branded Drug Class and Biosimilars Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 256: Iran 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Percentage Breakdown of Value Sales for Branded Drug Class and Biosimilars Drug Class for the Years 2014, 2024 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 259: Iran 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 262: Israel 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Percentage Breakdown of Value Sales for Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Branded Drug Class and Biosimilars Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Branded Drug Class and Biosimilars Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 265: Israel 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Percentage Breakdown of Value Sales for Branded Drug Class and Biosimilars Drug Class for the Years 2014, 2024 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 268: Israel 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 271: Saudi Arabia 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Percentage Breakdown of Value Sales for Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Branded Drug Class and Biosimilars Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Branded Drug Class and Biosimilars Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 274: Saudi Arabia 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Percentage Breakdown of Value Sales for Branded Drug Class and Biosimilars Drug Class for the Years 2014, 2024 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 277: Saudi Arabia 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 280: UAE 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Percentage Breakdown of Value Sales for Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Branded Drug Class and Biosimilars Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Branded Drug Class and Biosimilars Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 283: UAE 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Percentage Breakdown of Value Sales for Branded Drug Class and Biosimilars Drug Class for the Years 2014, 2024 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 286: UAE 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 289: Rest of Middle East 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Percentage Breakdown of Value Sales for Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Branded Drug Class and Biosimilars Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Branded Drug Class and Biosimilars Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 292: Rest of Middle East 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Percentage Breakdown of Value Sales for Branded Drug Class and Biosimilars Drug Class for the Years 2014, 2024 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 295: Rest of Middle East 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • AFRICA
    • Chemotherapy-Induced Neutropenia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 298: Africa 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Therapy Type - Percentage Breakdown of Value Sales for Granulocyte Colony-Stimulating Factors Therapy, Antibiotic Therapy, Granulocyte Transfusion Therapy and Other Therapy Types for the Years 2014, 2024 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Branded Drug Class and Biosimilars Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Branded Drug Class and Biosimilars Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 301: Africa 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Drug Class - Percentage Breakdown of Value Sales for Branded Drug Class and Biosimilars Drug Class for the Years 2014, 2024 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 304: Africa 16-Year Perspective for Chemotherapy-Induced Neutropenia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030

IV. COMPETITION